ライフサイエンスコーパス: platinum

1 and resensitize resistant ovarian tumors to platinum.

2 nd compared to the state-of-the-art catalyst platinum.

3 her transition metal catalysts also, such as platinum.

4 more endergonic on tungsten carbide than on platinum.

5 production of rare elements such as gold and platinum.

6 ce and auxiliary electrodes were composed of platinum.

7 ast 6 months following last infused cycle of platinum.

8 ) at an overpotential of 0.3 V comparable to platinum (0.44 V)].

9 In addition, elevated platinum abundances were found in sediment analysed from

10 n our approach allows the differentiation of platinum accumulation within each part of the morphology

11 ed to a naphthalene-monoimide acceptor via a platinum-acetylide bridging unit.

12 kinase-anchoring protein 12 (AKAP12) impeded platinum adduct clearance and prevented cAMP-mediated en

13 tinum and gold against Enterococcus faecium, platinum against Klebsiella pneumoniae and platinum and

14 otherapy with a fluorinated pyrimidine and a platinum agent, followed by later treatment with taxanes

15 mble of pre-cyclization conformations of the platinum-alkene reactant complex, only a subset of which

16 e useful for the future design of structured platinum alloy nanocatalysts.Core-shell platinum alloy n

17 ured platinum alloy nanocatalysts.Core-shell platinum alloy nanoparticles are promising catalysts for

18 The catalytic performance of core-shell platinum alloy nanoparticles is typically superior to th

19 Cisplatin and its platinum analogs, carboplatin and oxaliplatin, are some

20 g electrode and counter electrode consist of platinum and are functionalized by drop casting of three

21 lated disease progression within 6 months of platinum and cetuximab treatment.

22 d neck squamous cell carcinoma refractory to platinum and cetuximab.

23 amous cell carcinoma previously treated with platinum and cetuximab.

24 energetically less costly for gold than for platinum and explains the propensity of gold to facilita

25 ITO, gold, platinum and glass were tested and the amount of superox

26 robial inhibitory concentration demonstrated platinum and gold against Enterococcus faecium, platinum

27 nts of the electrocatalyst [Mo(bpy)(CO)4] at platinum and gold electrodes.

28 nt for precious group metals as for example, platinum and opens up new ways in finding cost-efficient

29 Platinum and palladium are frequently used as catalytic

30 ombination and increased sensitivity to both platinum and PARP inhibitor chemotherapy compared to Trp

31 , platinum against Klebsiella pneumoniae and platinum and silver against Acinetobacter baumannii were

32 d by understanding the mechanisms underlying platinum and taxane resistance in ovarian cancer.

33 rogrammed death 1 receptor antibody, in this platinum- and cetuximab-pretreated population with poor

34 eaction coordinates for polycyclization, for platinum- and enzyme-promoted polycyclization reactions

35 sm of action of these clinically established platinum anti-cancer agents, as well as more recently de

36 are proved to have comparable activities to platinum ( approximately 1-10 s(-1) ).

37 aditional electrodes, such as carbon or gold/platinum, are costly and difficult to microfabricate.

38 s, crucial for oxidation catalysts.Improving platinum as an oxidation catalyst requires understanding

39 the closest observed to the desired value of platinum at (-0.25 V vs. SCE).

40 talyst can be prepared by simple doping of a platinum atom into a molecule-like gold nanocluster.

41 ngle-pyridinic-nitrogen-atom-anchored single-platinum-atom centres, which are tolerant to carbon mono

42 the 3D coordinates of 6,569 iron and 16,627 platinum atoms in an iron-platinum nanoparticle, and cor

43 HER) as an alternative to currently utilised platinum based electrodes (with in electrolysers) is als

44 The platinum-based anticancer agents cisplatin, carboplatin,

45 ) randomly assigned to clinical trials using platinum-based chemoradiotherapy (NRG Oncology Radiation

46 Mitomycin and platinum-based chemotherapeutic agents were used in 96 (

47 e technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m(2) or ca

48 logram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 w

49 Purpose Platinum-based chemotherapy (PBC) for patients with prog

50 -small cell lung cancer (NSCLC) treated with platinum-based chemotherapy (PBS).

51 ARF failed to respond to treatment with the platinum-based chemotherapy agent cisplatin.

52 sensitive to clonogenic killing mediated by platinum-based chemotherapy and IR ( approximately 70%-8

53 with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 exp

54 ve as an efficacious and safe alternative to platinum-based chemotherapy before autologous stem cell

55 Platinum-based chemotherapy doublets are a standard of c

56 gainst VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamo

57 acebo after response to second-line or later platinum-based chemotherapy in patients with high-grade,

58 the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients.

59 OBS) after primary cytoreductive surgery and platinum-based chemotherapy in women with stage II to IV

60 disease progression on or after one previous platinum-based chemotherapy regimen in the metastatic se

61 despite previous treatment with at least one platinum-based chemotherapy regimen.

62 arcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved compl

63 t had progressed after at least one previous platinum-based chemotherapy were enrolled from 80 cancer

64 rothelial carcinoma who had progressed after platinum-based chemotherapy were randomly assigned (1:1)

65 nd disease progression during or after prior platinum-based chemotherapy were randomly assigned 1:1 t

66 e status (0 vs 1), previous radiosensitising platinum-based chemotherapy, and disease status (recurre

67 : treatment with primary surgery followed by platinum-based chemotherapy, stage II to IV disease, at

68 and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free f

69 echanisms underlying resistance to frontline platinum-based chemotherapy.

70 or partial response to second-line or later platinum-based chemotherapy.

71 ial carcinoma who progressed during or after platinum-based chemotherapy.

72 mic carcinoma (TC) who have progressed after platinum-based chemotherapy.

73 a (CCC) and the cancer is often resistant to platinum-based chemotherapy.

74 urothelial carcinoma after progression with platinum-based chemotherapy.

75 panib in urothelial cancers after failure of platinum-based chemotherapy.

76 nd neck who progressed within 6 months after platinum-based chemotherapy.

77 varian cancer who had achieved a response to platinum-based chemotherapy.

78 thway may improve the anticancer efficacy of platinum-based chemotherapy.

79 eviously progressed following crizotinib and platinum-based doublet chemotherapy.

80 we show that RAD6 plays a universal role in platinum-based drug tolerance.

81 have fueled multidisciplinary research into platinum-based drugs.

82 calable production of surfactant-free, thin, platinum-based nanowire-network electrocatalysts.

83 hod, different substrate-materials-supported platinum-based nanowires are obtained, which paves the w

84 egimen, and best response to the most recent platinum-based regimen).

85 gression-free interval after the penultimate platinum-based regimen, and best response to the most re

86 d complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concent

87 r two chemotherapeutic regimens, including a platinum-based regimen.

88 ed longer progression-free survival than did platinum-based therapy in patients with treatment-naive,

89 key mechanism associated with resistance to platinum-based therapy, a finding that we subsequently e

90 e kinase inhibitors, mitotic inhibitors, and platinum-based therapy, there is a need to stratify pati

91 Described herein is that the platinum (boryl)iminomethane (BIM) complex [Pt(kappa(2)

92 of [3](2+) occurs through abstraction of the platinum-bound chloride ligand by the adjacent Lewis aci

93 It is even better than the benchmarking platinum catalyst.

94 igration reaction leads to activation of the platinum center.

95 ation was stratified by response to previous platinum chemotherapy (complete vs partial) and length o

96 d overall survival after DNA damage-inducing platinum chemotherapy.

97 er-intuitive core-shell formation process in platinum-cobalt nanoparticles at elevated temperature un

98 n (FIC) studies demonstrated that the silver/platinum combination against Enterococcus faecium, and s

99 Toward this end, we have synthesized a platinum complex in which the metal is connected to a Le

100 led to clinical implementation of effective platinum complexes in the clinic have fueled multidiscip

101 Understanding the mechanisms of platinum compound resistance, including cisplatin resist

102 a significant reduction of the intracellular platinum concentration.

103 , high-performance electrocatalysts with low platinum consumption are desirable for use as cathode ma

104 ur methodology in rats using an experimental platinum-containing anti-cancer nanodrug and three FDA a

105 w treatment options following progression on platinum-containing chemotherapy.

106 ive effect on the anti-tumor efficacy of the platinum-containing nanodrug, as well as animal survival

107 urs, surpassing both the baseline Nafion and platinum-containing recast Nafion membranes.

108 opy with glassy carbon working electrode and platinum counter/reference electrode at a potential of 0

109 wed the atom-by-atom fabrication of isolated platinum deposits, ranging from single atoms to 9-atom c

110 (rituximab, dexamethasone, cytarabine, and a platinum derivative [R-DHAP]), the overall response rate

111 A dual-function platinum disc microelectrode sensor was used for in-situ

112 ed into the solution, from which the rate of platinum dissolution could be determined.

113 lieved to be the species responsible for the platinum dissolution phenomenon.

114 Within the PLATINUM Diversity cohort, the independent predictors of

115 of health and language were collected in the PLATINUM Diversity cohort, which included 1501 patients

116 s to cisplatin, consistent with shielding of platinum-DNA adducts from excision repair.

117 the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as wel

118 chemotherapy (one or two lines, including a platinum doublet) and crizotinib and had subsequent dise

119 y 3 weeks (35 cycles) or investigator-choice platinum-doublet chemotherapy (4-6 cycles or until docum

120 ated an epigenetic signature associated with platinum drug resensitization that may offer utility in

121 parameter most consistently associated with platinum drug resistance, emphasizing the need to direct

122 insights into the vital role of RAD6/TLS in platinum drug tolerance and reveal clinical benefits of

123 Platinum drug-induced cross-link repair requires the con

124 D6B depletion were associated with decreased platinum drug-induced proliferating cell nuclear antigen

125 1-mutant cancer cells is being targeted with platinum drugs and poly (ADP-ribose) polymerase (PARP) i

126 chanistically informed selection of distinct platinum drugs for distinct malignancies.

127 ve been implicated in acquired resistance to platinum drugs in ovarian cancer.

128 carboplatin derivative to quantify and track platinum drugs in tumors using PET has the potential to

129 lation can sensitize ovarian cancer cells to platinum drugs, in large part by altering gene expressio

130 revealed by scrutinizing what happens at the platinum electrode surface.

131 n of methanol from the reduction of CO2 on a platinum electrode triggered great interest and exciteme

132 ave developed simple sensors containing only platinum electrodes for the detection of heavy metal con

133 f "hydrogen" adsorption in the step sites of platinum electrodes.

134 ternative catalysts to noble metals, such as platinum, for the hydrogen evolution reaction (HER).

135 otherapy (complete vs partial) and length of platinum-free interval (6-12 months vs >/=12 months) and

136 e interval from previous platinum treatment (platinum-free interval [PFI]).

137 Platinum genotypes are highly concordant with the curren

138 the greatest bactericidal activity was again platinum gold and palladium against all three bacteria.

139 Platinum, gold and palladium showed the greatest antimic

140 ested in combinations using ZoI assays, gold/platinum, gold/palladium and platinum/palladium were ind

141 ny other elements (e.g., Ni, Co, Au, Se, and platinum group elements) are significantly less abundant

142 It remains a grand challenge to replace platinum group metal (PGM) catalysts with earth-abundant

143 Platinum group metal-free (PGM-free) metal-nitrogen-carb

144 tion (ORR) or hydrogen peroxide reduction on platinum, has been investigated.

145 work on phosphorescent, low molecular weight platinum(II) complex as an oxygen sensing probe to study

146 platinum(IV) complex, the in situ generated platinum(II) complex has good affinity for G-quadruplex

147 y reduced to the corresponding square planar platinum(II) complex.

148 bly conjugated to a mAb using a bifunctional platinum(II) linker.

149 The ethylenediamine platinum(II) moiety, herein called Lx, was coordinated t

150 An underlying platinum(ii) octaethlporphyrin ketone (PtOEPK) based sen

151 ), silver(I), mercury(II), copper(I and II), platinum(II), and cationic gold(I) are effective for rea

152 (III), gold(III), nickel(II), palladium(II), platinum(II), rhodium(III), iridium(III), and ruthenium(

153 e synthesis and in-depth characterization of platinum(II)-crosslinked single-chain nanoparticles (Pt(

154 ssemble into heavy elements such as gold and platinum in a process known as rapid neutron capture (r-

155 to approximately 2.5 mum for phosphorus and platinum in HCT116 colon cancer spheroids upon treatment

156 435 is necessary for cAMP-enhanced repair of platinum-induced damage and protection against cisplatin

157 excision repair (NER) plays a vital role in platinum-induced DNA damage during chemotherapy.

158 H- but not forskolin-mediated enhancement of platinum-induced DNA damage.

159 ccelerates repair of bi- and mono-functional platinum-induced DNA damage.

160 The platinum-induced fatty acid 16:4(n-3) (hexadeca-4,7,10,1

161 tical regulator of genomic stability against platinum-induced mutagenesis.

162 tissue, cisplatin-resistant tumors excluded platinum ions from tumor areas in contrast to cisplatin-

163 detection technique which involves reducing platinum ions to platinum metal species followed by an e

164 nally, the detection method demonstrates the platinum is dissolved into the solution as an ionic spec

165 A photoactivatable dopamine-conjugated platinum(IV) anticancer complex (Pt-DA) has been incorpo

166 In contrast to the parent platinum(IV) complex, the in situ generated platinum(II)

167 We show that a new octahedral platinum(IV)-salphen complex does not interact with DNA

168 emorial Center in Mumbai, India, reached its platinum jubilee milestone (75 years), which was celebra

169 to 680 mW cm(-2) at 80 degrees C with a low platinum loading of 0.09 mgPt cm(-2), corresponding to a

170 way as to include an interaction between the platinum metal center and the surface oxygen atoms.

171 allowed the quantification of the amount of platinum metal dissolved into the solution, from which t

172 que which involves reducing platinum ions to platinum metal species followed by an electrocatalytic a

173 similar potentials to those for reduction on platinum metal, suggesting a similar mechanism and kinet

174 measured the thermal conductance of gold and platinum metallic wires down to single-atom junctions.

175 In the present work, we used ceramic-based platinum microelectrode arrays (MEAs) to perform high-fr

176 ated in the perioperative setting, including platinum-naive patients, were also eligible.

177 We believe that the use of a platinum nanocell and single molecule/nanoparticle fluor

178 Herein, we report ultrasmall platinum nanoclusters (PtNCs) encapsulated in amine-func

179 gle silver nanoparticles at the surface of a platinum nanoelectrode.

180 A nanocell is prepared by depositing a platinum nanoparticle at the tip of a quartz nanopipette

181 evolution biocatalyst based on photosystem 1-platinum nanoparticle biocomplexes embedded into a speci

182 tion fine structure analysis confirm similar platinum nanoparticle shapes, sizes, lattice parameters,

183 69 iron and 16,627 platinum atoms in an iron-platinum nanoparticle, and correlate chemical order/diso

184 We report citrate-capped platinum nanoparticles (Pt NPs) as oxidase mimetics for

185 puttering and e-beam lithography techniques, platinum nanoparticles (Pt NPs) were deposited in a brid

186 eme using methylene blue (MB), hydrazine and platinum nanoparticles (Pt NPs).

187 acrylonitrile (PAN) nanofibrous web and then platinum nanoparticles (Pt-NP) decoration was performed

188 In this respect, platinum nanoparticles (PtNPs) are promising candidates,

189 Template-prepared rGO/platinum nanoparticles (PtNPs) tubular micromotors were

190 ease the rate of mass transfer of silver and platinum nanoparticles and improve their stochastic elec

191 lulose (NC)-based composites with silver and platinum nanoparticles as additive materials to fabricat

192 ticles is typically superior to that of pure platinum nanoparticles for the oxygen reduction reaction

193 When combined with platinum nanoparticles positioned on the external surfac

194 Here we report that platinum nanoparticles supported on graphite-rich boron

195 osome payload (dextran, single-stranded DNA, platinum nanoparticles) is trafficked into the attached

196 ified and then was decorated with silver and platinum nanoparticles, respectively, by chemical reduct

197 lity compared to commercial carbon supported platinum nanoparticles.

198 It reveals that the free-standing platinum nanowires form in the solid state via metal-sur

199 possess a high density of interfaces between platinum-nickel and nickel sulfide components, which coo

200 ctly sulfuring highly composition-segregated platinum-nickel nanowires.

201 The platinum-nickel/nickel sulfide heterostructures can deli

202 Using dealloyed nanoporous nickel-platinum (np-NiPt) electrodes, we find the hydrogen evol

203 d earth abundant metal catalyst which rivals platinum on a weight basis over hundreds of hours of ope

204 Overall, platinum, palladium and gold metal ion solutions in indi

205 Ten permutations of noble and base metals (platinum, palladium, copper, nickel, and cobalt) were sy

206 ectrochemical genosensor based on Zinc oxide/platinum-palladium (ZnO/Pt-Pd) modified fluorine doped t

207 oI assays, gold/platinum, gold/palladium and platinum/palladium were indicative of synergy.

208 Antitumour activity was assessed in post-platinum patients who received at least one dose of avel

209 In 161 post-platinum patients with at least 6 months of follow-up, a

210 ess antitumour activity of this drug in post-platinum patients.

211 eaching 18,046 moles of hydrogen per mole of platinum per hour.

212 tive second-line treatment for patients with platinum-pretreated recurrent or metastatic squamous cel

213 quantum chemical computations on a series of platinum-promoted polycyclization reactions are describe

214 e demonstrate how atomically dispersed ionic platinum (Pt(2+)) on ceria (CeO2), which is already ther

215 Previously, a large platinum (Pt) anomaly was reported in the Greenland ice

216 Here we report that platinum (Pt) atomically dispersed on alpha-molybdenum c

217 he identical device employing an unselective platinum (Pt) cathode.

218 This is demonstrated for platinum (Pt) nanoparticle surface reconstruction induce

219 o-electrocorticography (mu-ECoG) arrays with platinum (Pt) or glassy carbon (GC) electrodes were manu

220 ts are unique in their ability to trap ionic platinum (Pt), providing exceptional stability for isola

221 d as a promising alternative to their costly platinum (Pt)-based counterparts in polymer electrolyte

222 tretchable, and inexpensive devices based on platinum (Pt)-decorated graphite for glucose determinati

223 The stability of the platinum quasi-reference electrode was improved by coati

224 Initial segregation of a thin platinum, rather than cobalt oxide, surface layer occurs

225 sm of action are available for patients with platinum-refractory advanced or metastatic urothelial ca

226 survival over chemotherapy in patients with platinum-refractory advanced urothelial carcinoma.

227 with small-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or p

228 use of HDCT as third-line or later therapy, platinum-refractory disease, mediastinal primary tumor s

229 survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma over

230 r activity in the treatment of patients with platinum-refractory metastatic urothelial carcinoma; a m

231 Patients with platinum-refractory recurrent or metastatic squamous cel

232 py of investigator's choice in patients with platinum-refractory recurrent or metastatic squamous cel

233 The combination seems particularly active in platinum-refractory small-cell lung cancer, which tends

234 We used superresolution light microscopy and platinum replica transmission electron microscopy (TEM)

235 Cell unroofing and platinum replication creates high-contrast, 3D images of

236 ioning, whole-cell mount, cell unroofing and platinum replication, and resin embedding and sectioning

237 g group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung

238 undergoing autophagic stress independent of platinum resistance status.

239 an cancer stem cells that contribute to both platinum-resistance and tumour recurrence.

240 imary patient-derived platinum-sensitive and platinum- resistant ovarian cancer cells and ovarian can

241 argeting may improve therapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part

242 rial of IMGN853 monotherapy in patients with platinum-resistant disease.

243 Patients and Methods Patients with platinum-resistant epithelial ovarian, fallopian tube, o

244 phase 1 study, patients with progressive or platinum-resistant metastatic or recurrent NSCLC were en

245 bitor olaparib, and improved the response of platinum-resistant models.

246 red the responses of patients with recurrent platinum-resistant ovarian cancer who received carboplat

247 erived xenograft model of advanced-stage and platinum-resistant ovarian cancer, an MMAE-based NDC dou

248 manageable safety profile and was active in platinum-resistant ovarian cancer, with the strongest si

249 lation of patients with FRalpha-positive and platinum-resistant ovarian cancer.

250 Treatment of mice harboring platinum-resistant ovarian tumor xenografts with pHLIP-P

251 trial in patients with platinum-sensitive or platinum-resistant relapsed SCLC.

252 The cathodic dissolution of platinum, resulting from the oxygen reduction reaction (

253 P2) data that indicated atmospheric input of platinum-rich dust.

254 esting potentially predicting sensitivity to platinum salts and PARP inhibitors, the data regarding s

255 ities to promote HR and confer resistance to platinum salts and PARP inhibitors.

256 robust cell death in primary patient-derived platinum-sensitive and platinum- resistant ovarian cance

257 iagnosis and upon relapse from patients with platinum-sensitive HGSOC recurrence who were treated > 5

258 favor of an NPBC in patients with partially platinum-sensitive OC.

259 f a clinical efficacy trial in patients with platinum-sensitive or platinum-resistant relapsed SCLC.

260 idered a new standard of care for women with platinum-sensitive ovarian cancer following a complete o

261 d progression-free survival in patients with platinum-sensitive ovarian cancer who had achieved a res

262 sed to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit fro

263 rapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.

264 h BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucap

265 the median overall survival in patients with platinum-sensitive recurrent ovarian cancer.

266 In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were cl

267 patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ov

268 psule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian c

269 ted olaparib tablet maintenance treatment in platinum-sensitive, relapsed ovarian cancer patients wit

270 glucose oxidase-based biosensor, a sentinel platinum sensor, a laccase/tyrosinase-based biosensor an

271 , followed by the layer-by-layer growth of a platinum shell via Ostwald ripening during the oxygen an

272 l for atomic-scale design and control of the platinum shell, which is known to be the structural feat

273 ported cost-effective, efficient and durable platinum single-atom electrocatalyst with carbon monoxid

274 reveal that the main effective sites on such platinum single-atom electrocatalysts are single-pyridin

275 The electrode consists on platinum sputtered on a filter paper and a Nafion membra

276 id interface revealed that the adsorption on platinum supported catalysts of 1-(1-naphthyl)-ethylamin

277 and efficient method to generate a family of platinum supramolecular square complexes, including prev

278 n the ability of the amines to adsorb on the platinum surface and their performance as chiral modifie

279 However, experimental investigations of platinum surface oxides have been hampered by technical

280 s (t>/=4 h) is required for the formation of platinum surface oxides.

281 ve to drive the ORR or H2O2 reduction on the platinum surface, mainly using square wave potential pul

282 of the structure and degree of oxidation of platinum surfaces under operando conditions is essential

283 Although the combination of surgery and platinum-taxane chemotherapy provide an effective treatm

284 Although activity of platinum, the most active metal, can be substantially im

285 e OS for nonplatinum therapy was inferior to platinum therapy (median OS, 7.6 months [paclitaxel and

286 ss the safety profile in patients (both post-platinum therapy and cisplatin-naive) treated with avelu

287 ation potently sensitized resistant cells to platinum therapy and was effective in killing ovarian ca

288 atients with squamous histology who received platinum therapy compared with nonplatinum chemotherapy;

289 V = -0.071 +/- 0.003, comparable to that of platinum, theta Pt = 0.076 +/- 0.007, and is much larger

290 tment in a cohort of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC).

291 When applied to platinum-treated patients gathered from TCGA, the model

292 ve with a longer time interval from previous platinum treatment (platinum-free interval [PFI]).

293 progression 6 to 12 months after their last platinum treatment were randomly assigned 1:1 to the exp

294 ion of CO2 into CO, whose high affinity with platinum triggers the formation of a Pt-CO film that pre

295 esolved electrochemical measurements using a platinum ultramicroelectrode (UME) as the working electr

296 The OCP of platinum ultramicroelectrodes (UMEs) was determined in s

297 Platinum ultramicroelectrodes (UMEs) were polarized suff

298 The OCP at a platinum UME remains unchanged from the aqueous electrol

299 ding of 0.09 mgPt cm(-2), corresponding to a platinum utilization of 0.13 gPt kW(-1) in the fuel cell

300 transmission information to create a phased "Platinum" variant catalog of 4.7 million single-nucleoti

301 The dissolved platinum was detected using a femtomolar level detection